Sector Gamma AS Decreases Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Sector Gamma AS reduced its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 38.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 382,362 shares of the biopharmaceutical company's stock after selling 240,761 shares during the period. Gilead Sciences accounts for approximately 7.5% of Sector Gamma AS's investment portfolio, making the stock its 3rd biggest holding. Sector Gamma AS's holdings in Gilead Sciences were worth $30,975,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. OFI Invest Asset Management acquired a new position in Gilead Sciences during the 3rd quarter valued at about $26,000. Tompkins Financial Corp boosted its stake in Gilead Sciences by 223.1% during the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 241 shares during the last quarter. Fortitude Family Office LLC acquired a new position in Gilead Sciences during the 4th quarter valued at about $29,000. Rakuten Securities Inc. acquired a new position in Gilead Sciences during the 4th quarter valued at about $33,000. Finally, Financial Connections Group Inc. acquired a new position in Gilead Sciences during the 4th quarter valued at about $40,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Royal Bank of Canada cut their price target on Gilead Sciences from $76.00 to $74.00 and set a "sector perform" rating for the company in a research note on Friday. Mizuho dropped their target price on shares of Gilead Sciences from $101.00 to $90.00 and set a "buy" rating on the stock in a research report on Thursday, February 22nd. TD Cowen dropped their target price on shares of Gilead Sciences from $90.00 to $85.00 and set a "buy" rating on the stock in a research report on Friday. HSBC raised shares of Gilead Sciences from a "reduce" rating to a "hold" rating and set a $69.00 target price on the stock in a research report on Wednesday. Finally, Oppenheimer reissued an "outperform" rating and set a $105.00 target price on shares of Gilead Sciences in a research report on Friday, April 19th. Eleven research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $83.87.

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD traded up $0.15 during mid-day trading on Friday, reaching $65.42. The company had a trading volume of 12,382,425 shares, compared to its average volume of 6,443,315. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. The firm has a market cap of $81.45 billion, a price-to-earnings ratio of 181.72, a PEG ratio of 1.17 and a beta of 0.19. The company's 50-day moving average price is $71.28 and its 200-day moving average price is $76.25. Gilead Sciences, Inc. has a one year low of $64.63 and a one year high of $87.86.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, topping analysts' consensus estimates of ($1.49) by $0.17. The company had revenue of $6.69 billion for the quarter, compared to analysts' expectations of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 23.08%. Gilead Sciences's revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.37 EPS. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post 4.2 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be issued a dividend of $0.77 per share. The ex-dividend date is Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a yield of 4.71%. Gilead Sciences's payout ratio is 855.56%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business's stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $73.18, for a total transaction of $146,360.00. Following the sale, the insider now owns 100,936 shares of the company's stock, valued at approximately $7,386,496.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.16% of the company's stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.